Loading…

Predictors of Atrio-Ventricular Conduction Disease, Long-Term Outcomes in Patients with Myotonic Dystrophy Types I and II

Background:  Patients with myotonic dystrophy (DM) have an annual mortality of approximately 3.5%, one‐third of which is sudden cardiac death. The predictors of cardiac conduction disease in these patients are incompletely defined. Methods:  A single‐center cohort study included 211 patients with DM...

Full description

Saved in:
Bibliographic Details
Published in:Pacing and clinical electrophysiology 2012-10, Vol.35 (10), p.1262-1269
Main Authors: HA, ANDREW H., TARNOPOLSKY, MARK A., BERGSTRA, T. GRAHAM, NAIR, GIRISH M., AL-QUBBANY, ATIF, HEALEY, JEFF S.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4381-b17697259ba286bbc854d18b1af71215cecee88a0fd7972b8a1face18bc96b63
cites cdi_FETCH-LOGICAL-c4381-b17697259ba286bbc854d18b1af71215cecee88a0fd7972b8a1face18bc96b63
container_end_page 1269
container_issue 10
container_start_page 1262
container_title Pacing and clinical electrophysiology
container_volume 35
creator HA, ANDREW H.
TARNOPOLSKY, MARK A.
BERGSTRA, T. GRAHAM
NAIR, GIRISH M.
AL-QUBBANY, ATIF
HEALEY, JEFF S.
description Background:  Patients with myotonic dystrophy (DM) have an annual mortality of approximately 3.5%, one‐third of which is sudden cardiac death. The predictors of cardiac conduction disease in these patients are incompletely defined. Methods:  A single‐center cohort study included 211 patients with DM type 1 (DM1) and 25 DM type 2 (DM2). A severe electrocardiogram (ECG) abnormality was defined as a PR interval of ≥240 ms or QRS duration of ≥120 ms. Results:  A severe ECG abnormality was found in 24% of DM1 patients and 17% of DM2 patients. Among DM1 patients, those with a severe ECG abnormality were older (41.6 ± 14.6 vs 35.4 ± 12.6 years) and more likely to have hypertension (13.2% vs 4.2%, P = 0.038), heart failure (4.4% vs 0%, P = 0.056), atrial arrhythmias (6.6% vs 0.7%, P < 0.001), a higher number of trinucleotide repeats (689 ± 451 vs 474 ± 322, P = 0.01), and a family history of sudden cardiac death (26.7% vs 5.6%, P < 0.001) or pacemaker implantation (20% vs 0.7%, P < 0.001). Pacemakers or defibrillators were implanted in 14% of all patients, including 65% of patients with severe ECG abnormalities. During 57 ± 46 months, 13 patients died (1.16% per year), including three patients who died suddenly, two of whom had normally functioning pacemakers. Conclusion:  In DM1, atrio‐ventricular conduction disease is associated with increasing age, concomitant cardiovascular disease, nucleotide repeat length, and family history. The systematic identification of conduction disease and aggressive use of prophylactic pacemakers is associated with low rate of sudden cardiac death. (PACE 2012; 35:1262–1269)
doi_str_mv 10.1111/j.1540-8159.2012.03351.x
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1093480949</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1093480949</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4381-b17697259ba286bbc854d18b1af71215cecee88a0fd7972b8a1face18bc96b63</originalsourceid><addsrcrecordid>eNqNkM2O0zAURi0EYsrAKyBvkFiQ4J84cTZIVWcoRYUpUgRLy3EcxiWJO7ajad4eh5ayxZtryef7rnUAgBilOJ73-xSzDCUcszIlCJMUUcpwenwCFpeHp2CBcFYknPLyCrzwfo8QylHGnoMrQihnOCcLMO2cbowK1nloW7gMztjkux7iVGMnHVzZoRlVMHaAN8Zr6fU7uLXDz6TSrod3Y1C21x6aAe5kMDHo4aMJ9_DLZIMdjII3kw_OHu4nWE2HSG6gHBq42bwEz1rZef3qPK9B9fG2Wn1KtnfrzWq5TVRGOU5qXORlQVhZS8LzulacZQ3mNZZtgQlmSiutOZeobYrI1VziViodCVXmdU6vwdtT7cHZh1H7IHrjle46OWg7eoFRSTOOyqyMKD-hylnvnW7FwZleuilCYvYu9mLWK2a9YvYu_ngXxxh9fd4y1r1uLsG_oiPw5gxIr2TXOjko4_9xOctxxmjkPpy4R9Pp6b8_IHbL1e18jQXJqcD4oI-XAul-ibygBRM_vq4F_1xt1xn5Jkr6GzOHrmM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1093480949</pqid></control><display><type>article</type><title>Predictors of Atrio-Ventricular Conduction Disease, Long-Term Outcomes in Patients with Myotonic Dystrophy Types I and II</title><source>Wiley</source><source>SPORTDiscus with Full Text (EBSCO)</source><creator>HA, ANDREW H. ; TARNOPOLSKY, MARK A. ; BERGSTRA, T. GRAHAM ; NAIR, GIRISH M. ; AL-QUBBANY, ATIF ; HEALEY, JEFF S.</creator><creatorcontrib>HA, ANDREW H. ; TARNOPOLSKY, MARK A. ; BERGSTRA, T. GRAHAM ; NAIR, GIRISH M. ; AL-QUBBANY, ATIF ; HEALEY, JEFF S.</creatorcontrib><description>Background:  Patients with myotonic dystrophy (DM) have an annual mortality of approximately 3.5%, one‐third of which is sudden cardiac death. The predictors of cardiac conduction disease in these patients are incompletely defined. Methods:  A single‐center cohort study included 211 patients with DM type 1 (DM1) and 25 DM type 2 (DM2). A severe electrocardiogram (ECG) abnormality was defined as a PR interval of ≥240 ms or QRS duration of ≥120 ms. Results:  A severe ECG abnormality was found in 24% of DM1 patients and 17% of DM2 patients. Among DM1 patients, those with a severe ECG abnormality were older (41.6 ± 14.6 vs 35.4 ± 12.6 years) and more likely to have hypertension (13.2% vs 4.2%, P = 0.038), heart failure (4.4% vs 0%, P = 0.056), atrial arrhythmias (6.6% vs 0.7%, P &lt; 0.001), a higher number of trinucleotide repeats (689 ± 451 vs 474 ± 322, P = 0.01), and a family history of sudden cardiac death (26.7% vs 5.6%, P &lt; 0.001) or pacemaker implantation (20% vs 0.7%, P &lt; 0.001). Pacemakers or defibrillators were implanted in 14% of all patients, including 65% of patients with severe ECG abnormalities. During 57 ± 46 months, 13 patients died (1.16% per year), including three patients who died suddenly, two of whom had normally functioning pacemakers. Conclusion:  In DM1, atrio‐ventricular conduction disease is associated with increasing age, concomitant cardiovascular disease, nucleotide repeat length, and family history. The systematic identification of conduction disease and aggressive use of prophylactic pacemakers is associated with low rate of sudden cardiac death. (PACE 2012; 35:1262–1269)</description><identifier>ISSN: 0147-8389</identifier><identifier>EISSN: 1540-8159</identifier><identifier>DOI: 10.1111/j.1540-8159.2012.03351.x</identifier><identifier>PMID: 22385162</identifier><language>eng</language><publisher>Malden, USA: Blackwell Publishing Inc</publisher><subject>Adult ; Age Factors ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Arrhythmias, Cardiac - epidemiology ; atrio-ventricular block ; Atrioventricular Block - epidemiology ; Atrioventricular Block - therapy ; Biological and medical sciences ; Cardiac dysrhythmias ; Cardiology. Vascular system ; Cohort Studies ; Comorbidity ; Death, Sudden, Cardiac - epidemiology ; Death, Sudden, Cardiac - prevention &amp; control ; Defibrillators, Implantable ; Diseases of striated muscles. Neuromuscular diseases ; Electrocardiography ; Emergency and intensive care: neonates and children. Prematurity. Sudden death ; Female ; Heart ; Heart Failure - epidemiology ; Humans ; Hypertension - epidemiology ; Intensive care medicine ; Male ; Medical sciences ; Middle Aged ; Myotonic Disorders - epidemiology ; Myotonic Disorders - therapy ; myotonic dystrophy ; Myotonic Dystrophy - epidemiology ; Myotonic Dystrophy - therapy ; Neurology ; pacemaker ; Pacemaker, Artificial ; Prevalence ; Severity of Illness Index ; sudden death ; Treatment Outcome ; Trinucleotide Repeat Expansion - physiology</subject><ispartof>Pacing and clinical electrophysiology, 2012-10, Vol.35 (10), p.1262-1269</ispartof><rights>2012, The Authors. Journal compilation ©2012 Wiley Periodicals, Inc.</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4381-b17697259ba286bbc854d18b1af71215cecee88a0fd7972b8a1face18bc96b63</citedby><cites>FETCH-LOGICAL-c4381-b17697259ba286bbc854d18b1af71215cecee88a0fd7972b8a1face18bc96b63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=26561453$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22385162$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HA, ANDREW H.</creatorcontrib><creatorcontrib>TARNOPOLSKY, MARK A.</creatorcontrib><creatorcontrib>BERGSTRA, T. GRAHAM</creatorcontrib><creatorcontrib>NAIR, GIRISH M.</creatorcontrib><creatorcontrib>AL-QUBBANY, ATIF</creatorcontrib><creatorcontrib>HEALEY, JEFF S.</creatorcontrib><title>Predictors of Atrio-Ventricular Conduction Disease, Long-Term Outcomes in Patients with Myotonic Dystrophy Types I and II</title><title>Pacing and clinical electrophysiology</title><addtitle>Pacing Clin Electrophysiol</addtitle><description>Background:  Patients with myotonic dystrophy (DM) have an annual mortality of approximately 3.5%, one‐third of which is sudden cardiac death. The predictors of cardiac conduction disease in these patients are incompletely defined. Methods:  A single‐center cohort study included 211 patients with DM type 1 (DM1) and 25 DM type 2 (DM2). A severe electrocardiogram (ECG) abnormality was defined as a PR interval of ≥240 ms or QRS duration of ≥120 ms. Results:  A severe ECG abnormality was found in 24% of DM1 patients and 17% of DM2 patients. Among DM1 patients, those with a severe ECG abnormality were older (41.6 ± 14.6 vs 35.4 ± 12.6 years) and more likely to have hypertension (13.2% vs 4.2%, P = 0.038), heart failure (4.4% vs 0%, P = 0.056), atrial arrhythmias (6.6% vs 0.7%, P &lt; 0.001), a higher number of trinucleotide repeats (689 ± 451 vs 474 ± 322, P = 0.01), and a family history of sudden cardiac death (26.7% vs 5.6%, P &lt; 0.001) or pacemaker implantation (20% vs 0.7%, P &lt; 0.001). Pacemakers or defibrillators were implanted in 14% of all patients, including 65% of patients with severe ECG abnormalities. During 57 ± 46 months, 13 patients died (1.16% per year), including three patients who died suddenly, two of whom had normally functioning pacemakers. Conclusion:  In DM1, atrio‐ventricular conduction disease is associated with increasing age, concomitant cardiovascular disease, nucleotide repeat length, and family history. The systematic identification of conduction disease and aggressive use of prophylactic pacemakers is associated with low rate of sudden cardiac death. (PACE 2012; 35:1262–1269)</description><subject>Adult</subject><subject>Age Factors</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Arrhythmias, Cardiac - epidemiology</subject><subject>atrio-ventricular block</subject><subject>Atrioventricular Block - epidemiology</subject><subject>Atrioventricular Block - therapy</subject><subject>Biological and medical sciences</subject><subject>Cardiac dysrhythmias</subject><subject>Cardiology. Vascular system</subject><subject>Cohort Studies</subject><subject>Comorbidity</subject><subject>Death, Sudden, Cardiac - epidemiology</subject><subject>Death, Sudden, Cardiac - prevention &amp; control</subject><subject>Defibrillators, Implantable</subject><subject>Diseases of striated muscles. Neuromuscular diseases</subject><subject>Electrocardiography</subject><subject>Emergency and intensive care: neonates and children. Prematurity. Sudden death</subject><subject>Female</subject><subject>Heart</subject><subject>Heart Failure - epidemiology</subject><subject>Humans</subject><subject>Hypertension - epidemiology</subject><subject>Intensive care medicine</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Myotonic Disorders - epidemiology</subject><subject>Myotonic Disorders - therapy</subject><subject>myotonic dystrophy</subject><subject>Myotonic Dystrophy - epidemiology</subject><subject>Myotonic Dystrophy - therapy</subject><subject>Neurology</subject><subject>pacemaker</subject><subject>Pacemaker, Artificial</subject><subject>Prevalence</subject><subject>Severity of Illness Index</subject><subject>sudden death</subject><subject>Treatment Outcome</subject><subject>Trinucleotide Repeat Expansion - physiology</subject><issn>0147-8389</issn><issn>1540-8159</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNqNkM2O0zAURi0EYsrAKyBvkFiQ4J84cTZIVWcoRYUpUgRLy3EcxiWJO7ajad4eh5ayxZtryef7rnUAgBilOJ73-xSzDCUcszIlCJMUUcpwenwCFpeHp2CBcFYknPLyCrzwfo8QylHGnoMrQihnOCcLMO2cbowK1nloW7gMztjkux7iVGMnHVzZoRlVMHaAN8Zr6fU7uLXDz6TSrod3Y1C21x6aAe5kMDHo4aMJ9_DLZIMdjII3kw_OHu4nWE2HSG6gHBq42bwEz1rZef3qPK9B9fG2Wn1KtnfrzWq5TVRGOU5qXORlQVhZS8LzulacZQ3mNZZtgQlmSiutOZeobYrI1VziViodCVXmdU6vwdtT7cHZh1H7IHrjle46OWg7eoFRSTOOyqyMKD-hylnvnW7FwZleuilCYvYu9mLWK2a9YvYu_ngXxxh9fd4y1r1uLsG_oiPw5gxIr2TXOjko4_9xOctxxmjkPpy4R9Pp6b8_IHbL1e18jQXJqcD4oI-XAul-ibygBRM_vq4F_1xt1xn5Jkr6GzOHrmM</recordid><startdate>201210</startdate><enddate>201210</enddate><creator>HA, ANDREW H.</creator><creator>TARNOPOLSKY, MARK A.</creator><creator>BERGSTRA, T. GRAHAM</creator><creator>NAIR, GIRISH M.</creator><creator>AL-QUBBANY, ATIF</creator><creator>HEALEY, JEFF S.</creator><general>Blackwell Publishing Inc</general><general>Wiley</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201210</creationdate><title>Predictors of Atrio-Ventricular Conduction Disease, Long-Term Outcomes in Patients with Myotonic Dystrophy Types I and II</title><author>HA, ANDREW H. ; TARNOPOLSKY, MARK A. ; BERGSTRA, T. GRAHAM ; NAIR, GIRISH M. ; AL-QUBBANY, ATIF ; HEALEY, JEFF S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4381-b17697259ba286bbc854d18b1af71215cecee88a0fd7972b8a1face18bc96b63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Age Factors</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Arrhythmias, Cardiac - epidemiology</topic><topic>atrio-ventricular block</topic><topic>Atrioventricular Block - epidemiology</topic><topic>Atrioventricular Block - therapy</topic><topic>Biological and medical sciences</topic><topic>Cardiac dysrhythmias</topic><topic>Cardiology. Vascular system</topic><topic>Cohort Studies</topic><topic>Comorbidity</topic><topic>Death, Sudden, Cardiac - epidemiology</topic><topic>Death, Sudden, Cardiac - prevention &amp; control</topic><topic>Defibrillators, Implantable</topic><topic>Diseases of striated muscles. Neuromuscular diseases</topic><topic>Electrocardiography</topic><topic>Emergency and intensive care: neonates and children. Prematurity. Sudden death</topic><topic>Female</topic><topic>Heart</topic><topic>Heart Failure - epidemiology</topic><topic>Humans</topic><topic>Hypertension - epidemiology</topic><topic>Intensive care medicine</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Myotonic Disorders - epidemiology</topic><topic>Myotonic Disorders - therapy</topic><topic>myotonic dystrophy</topic><topic>Myotonic Dystrophy - epidemiology</topic><topic>Myotonic Dystrophy - therapy</topic><topic>Neurology</topic><topic>pacemaker</topic><topic>Pacemaker, Artificial</topic><topic>Prevalence</topic><topic>Severity of Illness Index</topic><topic>sudden death</topic><topic>Treatment Outcome</topic><topic>Trinucleotide Repeat Expansion - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HA, ANDREW H.</creatorcontrib><creatorcontrib>TARNOPOLSKY, MARK A.</creatorcontrib><creatorcontrib>BERGSTRA, T. GRAHAM</creatorcontrib><creatorcontrib>NAIR, GIRISH M.</creatorcontrib><creatorcontrib>AL-QUBBANY, ATIF</creatorcontrib><creatorcontrib>HEALEY, JEFF S.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pacing and clinical electrophysiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HA, ANDREW H.</au><au>TARNOPOLSKY, MARK A.</au><au>BERGSTRA, T. GRAHAM</au><au>NAIR, GIRISH M.</au><au>AL-QUBBANY, ATIF</au><au>HEALEY, JEFF S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Predictors of Atrio-Ventricular Conduction Disease, Long-Term Outcomes in Patients with Myotonic Dystrophy Types I and II</atitle><jtitle>Pacing and clinical electrophysiology</jtitle><addtitle>Pacing Clin Electrophysiol</addtitle><date>2012-10</date><risdate>2012</risdate><volume>35</volume><issue>10</issue><spage>1262</spage><epage>1269</epage><pages>1262-1269</pages><issn>0147-8389</issn><eissn>1540-8159</eissn><abstract>Background:  Patients with myotonic dystrophy (DM) have an annual mortality of approximately 3.5%, one‐third of which is sudden cardiac death. The predictors of cardiac conduction disease in these patients are incompletely defined. Methods:  A single‐center cohort study included 211 patients with DM type 1 (DM1) and 25 DM type 2 (DM2). A severe electrocardiogram (ECG) abnormality was defined as a PR interval of ≥240 ms or QRS duration of ≥120 ms. Results:  A severe ECG abnormality was found in 24% of DM1 patients and 17% of DM2 patients. Among DM1 patients, those with a severe ECG abnormality were older (41.6 ± 14.6 vs 35.4 ± 12.6 years) and more likely to have hypertension (13.2% vs 4.2%, P = 0.038), heart failure (4.4% vs 0%, P = 0.056), atrial arrhythmias (6.6% vs 0.7%, P &lt; 0.001), a higher number of trinucleotide repeats (689 ± 451 vs 474 ± 322, P = 0.01), and a family history of sudden cardiac death (26.7% vs 5.6%, P &lt; 0.001) or pacemaker implantation (20% vs 0.7%, P &lt; 0.001). Pacemakers or defibrillators were implanted in 14% of all patients, including 65% of patients with severe ECG abnormalities. During 57 ± 46 months, 13 patients died (1.16% per year), including three patients who died suddenly, two of whom had normally functioning pacemakers. Conclusion:  In DM1, atrio‐ventricular conduction disease is associated with increasing age, concomitant cardiovascular disease, nucleotide repeat length, and family history. The systematic identification of conduction disease and aggressive use of prophylactic pacemakers is associated with low rate of sudden cardiac death. (PACE 2012; 35:1262–1269)</abstract><cop>Malden, USA</cop><pub>Blackwell Publishing Inc</pub><pmid>22385162</pmid><doi>10.1111/j.1540-8159.2012.03351.x</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0147-8389
ispartof Pacing and clinical electrophysiology, 2012-10, Vol.35 (10), p.1262-1269
issn 0147-8389
1540-8159
language eng
recordid cdi_proquest_miscellaneous_1093480949
source Wiley; SPORTDiscus with Full Text (EBSCO)
subjects Adult
Age Factors
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Arrhythmias, Cardiac - epidemiology
atrio-ventricular block
Atrioventricular Block - epidemiology
Atrioventricular Block - therapy
Biological and medical sciences
Cardiac dysrhythmias
Cardiology. Vascular system
Cohort Studies
Comorbidity
Death, Sudden, Cardiac - epidemiology
Death, Sudden, Cardiac - prevention & control
Defibrillators, Implantable
Diseases of striated muscles. Neuromuscular diseases
Electrocardiography
Emergency and intensive care: neonates and children. Prematurity. Sudden death
Female
Heart
Heart Failure - epidemiology
Humans
Hypertension - epidemiology
Intensive care medicine
Male
Medical sciences
Middle Aged
Myotonic Disorders - epidemiology
Myotonic Disorders - therapy
myotonic dystrophy
Myotonic Dystrophy - epidemiology
Myotonic Dystrophy - therapy
Neurology
pacemaker
Pacemaker, Artificial
Prevalence
Severity of Illness Index
sudden death
Treatment Outcome
Trinucleotide Repeat Expansion - physiology
title Predictors of Atrio-Ventricular Conduction Disease, Long-Term Outcomes in Patients with Myotonic Dystrophy Types I and II
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T15%3A55%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Predictors%20of%20Atrio-Ventricular%20Conduction%20Disease,%20Long-Term%20Outcomes%20in%20Patients%20with%20Myotonic%20Dystrophy%20Types%20I%20and%20II&rft.jtitle=Pacing%20and%20clinical%20electrophysiology&rft.au=HA,%20ANDREW%20H.&rft.date=2012-10&rft.volume=35&rft.issue=10&rft.spage=1262&rft.epage=1269&rft.pages=1262-1269&rft.issn=0147-8389&rft.eissn=1540-8159&rft_id=info:doi/10.1111/j.1540-8159.2012.03351.x&rft_dat=%3Cproquest_cross%3E1093480949%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4381-b17697259ba286bbc854d18b1af71215cecee88a0fd7972b8a1face18bc96b63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1093480949&rft_id=info:pmid/22385162&rfr_iscdi=true